Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease
Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia.
Sponsor: London School of Hygiene and Tropical Medicine
This PHASE1/PHASE2 trial investigates Malaria and Sickle Cell Crisis and is currently completed. London School of Hygiene and Tropical Medicine leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- London School of Hygiene and Tropical Medicine
- Medical Research Council Unit, The Gambia
- University of Ilorin Teaching Hospital
- Wellcome Trust
For direct contact, visit the study record on ClinicalTrials.gov .